...
首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >Diagnostic value of combined 1?F-FDG PET/MRI for staging and restaging in paediatric oncology.
【24h】

Diagnostic value of combined 1?F-FDG PET/MRI for staging and restaging in paediatric oncology.

机译:联合1?F-FDG PET / MRI对小儿肿瘤的分期和再分期的诊断价值。

获取原文
获取原文并翻译 | 示例

摘要

The present study compares the diagnostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and MRI to combined/registered (18)F-FDG PET/MRI for staging and restaging in paediatric oncology.Over 8 years and 2 months, 270 (18)F-FDG PET and 270 MRI examinations (mean interval 5 days) were performed in 132 patients with proven (n = 117) or suspected (n = 15) malignant disease: solid tumours (n = 64), systemic malignancy (n = 53) and benign disease (n = 15). A total of 259 suspected tumour lesions were analysed retrospectively during primary diagnosis and 554 lesions during follow-up. Image analysis was performed separately on each modality, followed by analysis of combined and registered (18)F-FDG PET/MRI imaging.A total of 813 lesions were evaluated and confirmed by histopathology (n = 158) and/or imaging follow-up (n = 655) after 6 months. In the separate analysis of (18)F-FDG PET and MRI, sensitivity was 86 %/94 % and specificity 85 %/38 %. Combined/registered (18)F-FDG PET/MRI led to a sensitivity of 97 %/97 % and specificity of 81 %/82 %. False-positive results ((18)F-FDG PET n = 69, MRI n = 281, combined (18)F-FDG PET/MRI n = 85, registered (18)F-FDG PET/MRI n = 80) were due to physiological uptake or post-therapeutic changes. False-negative results ((18)F-FDG PET n = 50, MRI n = 20, combined (18)F-FDG PET/MRI n = 11, registered (18)F-FDG PET/MRI n = 11) were based on low uptake or minimal morphological changes. Examination-based evaluation during follow-up showed a sensitivity/specificity of 91 %/81 % for (18)F-FDG PET, 93 %/30 % for MRI and 96 %/72 % for combined (18)F-FDG PET/MRI.For the detection of single tumour lesions, registered (18)F-FDG PET/MRI proved to be the methodology of choice for adequate tumour staging. In the examination-based evaluation, MRI alone performed better than (18)F-FDG PET and combined/registered imaging during primary diagnosis. At follow-up, however, the examination-based evaluation demonstrated a superiority of (18)F-FDG PET alone.
机译:本研究比较了(18)F-氟脱氧葡萄糖(FDG)正电子发射断层扫描(PET)和MRI与联合/注册的(18)F-FDG PET / MRI在小儿肿瘤中的分期和再分期的诊断价值。 2个月,对132例已证实(n = 117)或怀疑(n = 15)恶性疾病:实体瘤(n = 64)的患者进行了270(18)F-FDG PET和270 MRI检查(平均间隔5天) ,全身性恶性肿瘤(n = 53)和良性疾病(n = 15)。在初步诊断期间对总共259个可疑肿瘤病变进行了回顾性分析,在随访过程中对554个病变进行了回顾性分析。对每种方式分别进行图像分析,然后对组合和配准的(18)F-FDG PET / MRI成像进行分析。通过组织病理学(n = 158)和/或成像随访评估和确认了总共813个病变(n = 655)在6个月后。在(18)F-FDG PET和MRI的单独分析中,敏感性为86%/ 94%,特异性为85%/ 38%。组合/配准(18)F-FDG PET / MRI的敏感性为97%/ 97%,特异性为81%/ 82%。假阳性结果((18)F-FDG PET n = 69,MRI n = 281,合并(18)F-FDG PET / MRI n = 85,已注册(18)F-FDG PET / MRI n = 80)由于生理上的吸收或治疗后的变化。假阴性结果((18)F-FDG PET n = 50,MRI n = 20,合并(18)F-FDG PET / MRI n = 11,已注册(18)F-FDG PET / MRI n = 11)是基于低摄取或最小形态变化。随访期间基于检查的评估显示,(18)F-FDG PET的敏感性/特异性为91%/ 81%,MRI为93%/ 30%,联合(18)F-FDG PET为96%/ 72% / MRI。对于检测单个肿瘤病变,已注册的(18)F-FDG PET / MRI被证明是适当肿瘤分期的选择方法。在基于检查的评估中,在初次诊断期间,仅MRI表现优于(18)F-FDG PET和组合/配准成像。然而,在随访中,基于检查的评估证明了单独使用(18)F-FDG PET的优越性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号